200 related articles for article (PubMed ID: 28705885)
1. Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease.
Chonchol M; Gitomer B; Isakova T; Cai X; Salusky I; Pereira R; Abebe K; Torres V; Steinman TI; Grantham JJ; Chapman AB; Schrier RW; Wolf M
Clin J Am Soc Nephrol; 2017 Sep; 12(9):1461-1469. PubMed ID: 28705885
[TBL] [Abstract][Full Text] [Related]
2. Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials.
Brosnahan GM; Abebe KZ; Rahbari-Oskoui FF; Patterson CG; Bae KT; Schrier RW; Braun WE; Chapman AB; Flessner MF; Harris PC; Perrone RD; Steinman TI; Torres VE;
Curr Hypertens Rev; 2017; 13(2):109-120. PubMed ID: 28460625
[TBL] [Abstract][Full Text] [Related]
3. Serum Uric Acid and Progression of Autosomal Dominant Polycystic Kidney Disease: Results from the HALT PKD Trials.
Brosnahan GM; You Z; Wang W; Gitomer BY; Chonchol M
Curr Hypertens Rev; 2021; 17(3):228-237. PubMed ID: 32807060
[TBL] [Abstract][Full Text] [Related]
4. Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials.
Brosnahan GM; Abebe KZ; Moore CG; Rahbari-Oskoui FF; Bae KT; Grantham JJ; Schrier RW; Braun WE; Chapman AB; Flessner MF; Harris PC; Hogan MC; Perrone RD; Miskulin DC; Steinman TI; Torres VE;
Am J Kidney Dis; 2018 May; 71(5):666-676. PubMed ID: 29306517
[TBL] [Abstract][Full Text] [Related]
5. Soluble Urokinase Plasminogen Activator Receptor and Decline in Kidney Function in Autosomal Dominant Polycystic Kidney Disease.
Hayek SS; Landsittel DP; Wei C; Zeier M; Yu ASL; Torres VE; Roth S; Pao CS; Reiser J
J Am Soc Nephrol; 2019 Jul; 30(7):1305-1313. PubMed ID: 31171572
[TBL] [Abstract][Full Text] [Related]
6. Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease.
Torres VE; Abebe KZ; Schrier RW; Perrone RD; Chapman AB; Yu AS; Braun WE; Steinman TI; Brosnahan G; Hogan MC; Rahbari FF; Grantham JJ; Bae KT; Moore CG; Flessner MF
Kidney Int; 2017 Feb; 91(2):493-500. PubMed ID: 27993381
[TBL] [Abstract][Full Text] [Related]
7. Urinary Angiotensinogen in addition to Imaging Classification in the Prediction of Renal Outcome in Autosomal Dominant Polycystic Kidney Disease.
Park HC; Kim J; Cho A; Kim DH; Lee YK; Ryu H; Kim H; Oh KH; Oh YK; Hwang YH; Lee KB; Kim SW; Kim YH; Lee J; Ahn C;
J Korean Med Sci; 2020 Jun; 35(22):e165. PubMed ID: 32508065
[TBL] [Abstract][Full Text] [Related]
8. Long-term effect of coffee consumption on autosomal dominant polycystic kidneys disease progression: results from the Suisse ADPKD, a Prospective Longitudinal Cohort Study.
Girardat-Rotar L; Puhan MA; Braun J; Serra AL
J Nephrol; 2018 Feb; 31(1):87-94. PubMed ID: 28386880
[TBL] [Abstract][Full Text] [Related]
9. KIM-1 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease: HALT-PKD Results.
Griffin BR; You Z; Noureddine L; Gitomer B; Perrenoud L; Wang W; Chonchol M; Jalal D;
Am J Nephrol; 2020; 51(6):473-479. PubMed ID: 32541154
[TBL] [Abstract][Full Text] [Related]
10. Association between Monocyte Count and Risk of Incident CKD and Progression to ESRD.
Bowe B; Xie Y; Xian H; Li T; Al-Aly Z
Clin J Am Soc Nephrol; 2017 Apr; 12(4):603-613. PubMed ID: 28348030
[TBL] [Abstract][Full Text] [Related]
11. NT-proBNP and troponin T and risk of rapid kidney function decline and incident CKD in elderly adults.
Bansal N; Katz R; Dalrymple L; de Boer I; DeFilippi C; Kestenbaum B; Park M; Sarnak M; Seliger S; Shlipak M
Clin J Am Soc Nephrol; 2015 Feb; 10(2):205-14. PubMed ID: 25605700
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.
Edwards ME; Chebib FT; Irazabal MV; Ofstie TG; Bungum LA; Metzger AJ; Senum SR; Hogan MC; El-Zoghby ZM; Kline TL; Harris PC; Czerwiec FS; Torres VE
Clin J Am Soc Nephrol; 2018 Aug; 13(8):1153-1161. PubMed ID: 30026287
[TBL] [Abstract][Full Text] [Related]
13. Factors predicting decline in renal function and kidney volume growth in autosomal dominant polycystic kidney disease: a prospective cohort study (Japanese Polycystic Kidney Disease registry: J-PKD).
Uchiyama K; Mochizuki T; Shimada Y; Nishio S; Kataoka H; Mitobe M; Tsuchiya K; Hanaoka K; Ubara Y; Suwabe T; Sekine A; Nutahara K; Tsuruya K; Ishimura E; Nakatani S; Sofue T; Tanaka S; Narita I; Maruyama S; Horie S; Muto S
Clin Exp Nephrol; 2021 Sep; 25(9):970-980. PubMed ID: 33928479
[TBL] [Abstract][Full Text] [Related]
14. Determinants of Progression in Early Autosomal Dominant Polycystic Kidney Disease: Is it Blood Pressure or Renin-Angiotensin-Aldosterone-System Blockade?
Brosnahan GM; Abebe KZ; Moore CG; Bae KT; Braun WE; Chapman AB; Flessner MF; Harris PC; Hogan MC; Perrone RD; Rahbari-Oskoui FF; Steinman TI; Torres VE; The Halt Pkd Investigators
Curr Hypertens Rev; 2018; 14(1):39-47. PubMed ID: 29564978
[TBL] [Abstract][Full Text] [Related]
15. Soluble klotho and autosomal dominant polycystic kidney disease.
Pavik I; Jaeger P; Ebner L; Poster D; Krauer F; Kistler AD; Rentsch K; Andreisek G; Wagner CA; Devuyst O; Wüthrich RP; Schmid C; Serra AL
Clin J Am Soc Nephrol; 2012 Feb; 7(2):248-57. PubMed ID: 22193235
[TBL] [Abstract][Full Text] [Related]
16. Kidney Function Reserve Capacity in Early and Later Stage Autosomal Dominant Polycystic Kidney Disease.
Messchendorp AL; van Londen M; Taylor JM; de Borst MH; Navis G; Casteleijn NF; Gaillard CAJM; Bakker SJL; Gansevoort RT;
Clin J Am Soc Nephrol; 2018 Nov; 13(11):1680-1692. PubMed ID: 30254028
[TBL] [Abstract][Full Text] [Related]
17. Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial.
Irazabal MV; Abebe KZ; Bae KT; Perrone RD; Chapman AB; Schrier RW; Yu AS; Braun WE; Steinman TI; Harris PC; Flessner MF; Torres VE;
Nephrol Dial Transplant; 2017 Nov; 32(11):1857-1865. PubMed ID: 27484667
[TBL] [Abstract][Full Text] [Related]
18. Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.
Torres VE; Higashihara E; Devuyst O; Chapman AB; Gansevoort RT; Grantham JJ; Perrone RD; Ouyang J; Blais JD; Czerwiec FS;
Clin J Am Soc Nephrol; 2016 May; 11(5):803-811. PubMed ID: 26912543
[TBL] [Abstract][Full Text] [Related]
19. Alterations of Proximal Tubular Secretion in Autosomal Dominant Polycystic Kidney Disease.
Wang K; Zelnick LR; Chen Y; Hoofnagle AN; Watnick T; Seliger S; Kestenbaum B
Clin J Am Soc Nephrol; 2020 Jan; 15(1):80-88. PubMed ID: 31628117
[TBL] [Abstract][Full Text] [Related]
20. Higher beta-hydroxybutyrate ketone levels associated with a slower kidney function decline in ADPKD.
Knol MGE; Bais T; Geertsema P; Connelly MA; Bakker SJL; Gansevoort RT; van Gastel MDA;
Nephrol Dial Transplant; 2024 Apr; 39(5):838-847. PubMed ID: 37974030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
